Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06880523 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Study acronym: SLIDE-HCC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 12 to 13v10
  2. Site details revised at 1 of 12 sitesv9
  3. Study sites: 11 to 12v8
  4. Study sites: 10 to 11v7
  5. Study sites: 9 to 10v6
Show 4 earlier versionsHide 4 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 4 to 9
    • Start date changed from estimate of Sep 30, 2025 to Oct 21, 2025
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Study sites: 2 to 4v3
  4. Start date: May 31, 2025 to Sep 30, 2025
    • Study sites: 0 to 2
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.
Trial Details
NCT Number NCT06880523
Lead Sponsor Canadian Cancer Trials Group
Collaborators: AstraZeneca, National Cancer Institute, Naples
Conditions
(from sponsor)		 Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov